Category Filter
- Advanced Imaging
- Behavioral Health
- Chronic Condition Management
- Genetic Testing
- Hemophilia Drugs
- Medical Oncology Regimen Program
- Medical Policies
- Pre-Service Review (Precertification/Predetermination)
- Provider-Administered Drug Policies
- Radiation Therapy
- Self-Administered Drug Policies
- Transgender Services
Asset Publisher
Myalept (Metreleptin) Prior Authorization Program Summary
Policy Number: PH-1058
This program applies to Blue Partner, Commercial, GenPlus, NetResults A series, SourceRx and Health Insurance Marketplace formularies
POLICY REVIEW CYCLE
Effective Date |
Date of Origin |
1/1/2024 |
|
FDA APPROVED INDICATIONS AND DOSAGE
Agent(s) |
FDA Indication(s) |
Notes |
Ref# |
Myalept® (metreleptin) Subcutaneous injection |
Adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy Limitations of Use: - Safety and effectiveness for the treatment of complications of partial lipodystrophy have not been established - Safety and effectiveness for the treatment of liver disease, including nonalcoholic steatohepatitis (NASH), have not been established - Not indicated for use in patients with HIV-related lipodystrophy - Not indicated for use in patients with metabolic disease, including diabetes mellitus and hypertriglyceridemia, without concurrent evidence of congenital generalized lipodystrophy (CGL) or acquired generalized lipodystrophy (AGL) |
|
1 |
See package insert for FDA prescribing information: https://dailymed.nlm.nih.gov/dailymed/index.cfm
CLINICAL RATIONALE
Lipodystrophy |
Lipodystrophy is a rare, heterogeneous group of syndromes characterized by the complete or partial loss or absence of subcutaneous adipose tissue. The loss or absence of adipose tissue results in decreased levels of leptin, which is an important hormone regulating appetite. Lipodystrophy is often, although not always, accompanied by metabolic derangements, including insulin resistance, diabetes mellitus, hepatic steatosis or steatohepatitis, and dyslipidemia. Metabolic derangements associated with lipodystrophy can be severe and lead to substantial comorbidities, including acute pancreatitis (due to severe hypertriglyceridemia), hepatic cirrhosis, and premature cardiovascular disease.(2-5) Lipodystrophy can generally be classified based on extent or pattern of fat loss (generalized or partial) and whether the disease is genetic or acquired. There are 4 major lipodystrophy subtypes: congenital generalized lipodystrophy (CGL), acquired generalized lipodystrophy (AGL), familial partial lipodystrophy (FPL), and acquired partial lipodystrophy (APL).(2-4) Initial treatment of metabolic disturbances associated with lipodystrophy (e.g., diabetes, hypertriglyceridemia) is the same as in patients without lipodystrophy. Diabetes is treated with hyperglycemic drugs as well as insulin (although high doses are often required). Hypertriglyceridemia may be treated with statins, fibric acid derivatives, or omega-3 fatty acids. Individuals with CGL and AGL are encouraged to maintain a healthy weight by following a low-fat diet and engaging in regular exercise. If metabolic disturbances persist, metreleptin is recommended, along with careful monitoring, in these patients.(2,3,5) |
Efficacy (1) |
Metreleptin is a recombinant human leptin analog that functions by binding to and activating the human leptin receptor which studies suggest causes an increase in insulin sensitivity and a reduction in food intake. The efficacy of metreleptin was evaluated in an open label single arm study of 48 patients with congenital (n=32) or acquired (n=16) generalized lipodystrophy who also had at least one of the metabolic abnormalities [diabetes mellitus, hypertriglyceridemia > 200 mg/dL, and/or increased fasting insulin (greater than or equal to 30 µU/mL)]. At baseline, 37 (77%) patients had HbA1c values of 7% or greater, 19 (40%) had HbA1c values of 9% or greater, 33 (69%) had fasting plasma glucose values of 126 mg/dL or greater, 17 (35%) had fasting triglyceride values of 500 mg/dL or greater, and 11 (23%) had fasting triglyceride values of 1000 mg/dL or greater. The metreleptin treatment duration was 3.6 months to 10.9 years (median = 2.7 years) and metreleptin was administered either once or twice daily. At year 1, patients treated with metreleptin had mean/median reductions in HbA1c (-2%), fasting glucose (-49 mg/dL), and triglycerides (-55%). Concomitant anti-hyperglycemic and lipid-altering medications dosing regimens were not held constant throughout the study. |
Safety (1) |
Metreleptin has the following boxed warning for risk of anti-metreleptin antibodies with neutralizing activity and risk of lymphoma:
Due to the issues included in the boxed warning, metreleptin is available only through a restricted REMS program. Metreleptin is contraindicated in the following:
|
REFERENCES
Number |
Reference |
1 |
Myalept prescribing information. Aegerion Pharmaceuticals, Inc. February 2022. |
2 |
Handelsman Y, Oral EA, Bloomgarden Z. The Clinical Approach to the Detection of Lipodystrophy – An AACE Consensus Statement. Endocr Pract 2013;19(1):107-116. |
3 |
Brown R, Araujo-Vilar D, Pik T, et al. The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline. J Clin Endocrinol Metab 2016 Dec;101(12):4500-4511. |
4 |
Araujo-Vilar D, Santini F. Diagnosis and Treatment of Lipodystrophy: A Step-By-Step Approach. J Endocrinol Invest 2019;42(1):61-73. |
5 |
National Organization for Rare Disorders (NORD). Physician Guide to the Lipodystrophy Disorders. 2014. Available at: https://rarediseases.org/physician-guide/lipodystrophy-disorders/. |
POLICY AGENT SUMMARY PRIOR AUTHORIZATION
Target Brand Agent(s) |
Target Generic Agent(s) |
Strength |
Targeted MSC |
Available MSC |
Final Age Limit |
Preferred Status |
|
||||||
Myalept |
metreleptin for subcutaneous inj |
11.3 MG |
M ; N ; O ; Y |
N |
|
|
CLIENT SUMMARY – PRIOR AUTHORIZATION
Target Brand Agent Name(s) |
Target Generic Agent Name(s) |
Strength |
Client Formulary |
Myalept |
metreleptin for subcutaneous inj |
11.3 MG |
Blue Partner ; Commercial ; GenPlus ; Health Insurance Marketplace ; NetResults A Series ; SourceRx |
PRIOR AUTHORIZATION CLINICAL CRITERIA FOR APPROVAL
Module |
Clinical Criteria for Approval |
|
Initial Evaluation Target Agent will be approved when ALL of the following are met:
Length of Approval: 12 months
Renewal Evaluation Target Agent will be approved when ALL of the following are met:
Length of Approval: 12 months |
This pharmacy policy is not an authorization, certification, explanation of benefits or a contract. Eligibility and benefits are determined on a case-by-case basis according to the terms of the member’s plan in effect as of the date services are rendered. All pharmacy policies are based on (i) information in FDA approved package inserts (and black box warning, alerts, or other information disseminated by the FDA as applicable); (ii) research of current medical and pharmacy literature; and/or (iii) review of common medical practices in the treatment and diagnosis of disease as of the date hereof. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment.
The purpose of Blue Cross and Blue Shield of Alabama’s pharmacy policies are to provide a guide to coverage. Pharmacy policies are not intended to dictate to physicians how to practice medicine. Physicians should exercise their medical judgment in providing the care they feel is most appropriate for their patients.
Neither this policy, nor the successful adjudication of a pharmacy claim, is guarantee of payment.
Commercial _ PS _ Myalept (metreleptin) _PA _ProgSum_ 1/1/2024